dabigatran has been researched along with Embolus in 136 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (2.21) | 29.6817 |
2010's | 99 (72.79) | 24.3611 |
2020's | 34 (25.00) | 2.80 |
Authors | Studies |
---|---|
Alioğlu, E; Altın, C; Bilgin, N; Çetin, N; Dalgıç, O; Ekmekçi, C; Kocabaş, U; Özpelit, ME; Pekel, N; Topaloğlu, C; Tülüce, K; Tunçer, E; Türk, UÖ; Türkoğlu, Eİ; Yavuz, V; Yüksel, K | 1 |
de Vries, TI; Peters, RJG; Stam-Slob, MC; van der Graaf, Y; Visseren, FLJ; Westerink, J | 1 |
Atreja, N; Deitelzweig, S; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Luo, X; Schuler, P; Yuce, H; Zhang, Y | 1 |
Atarashi, H; Fukaya, T; Inoue, H; Koretsune, Y; Okumura, K; Uchiyama, S; Wakayama, J; Yamashita, T; Yasaka, M | 1 |
Amin, A; Dina, O; Hines, DM; Keshishian, A; Le, H; Liu, X; Rosenblatt, L; Vo, L; Zhang, Q | 1 |
Brewster, J; Hingorani, AD; Lau, WCY; Li, J; Lip, GYH; Man, KKC; Reich, C; Seager, S; Stewart, HM; Torre, CO; Van Zandt, M; Wei, L; Wong, ICK | 1 |
Atreja, N; Deitelzweig, S; Jenkins, A; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Schuler, P; Sun, X; Yuce, H | 1 |
Atreja, N; Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Keshishian, A; Russ, C; Yuce, H | 1 |
Aronow, HD; Hume, AL; Lawal, OD; Matson, KL; Shobayo, F; Taveira, TH; Wen, X; Zhang, Y | 1 |
Altın, C; Aslan, O; Bilgel, ZG; Boyraz, B; Çakal, S; Çayırlı, S; Çoner, A; Coşgun, MS; Dal, A; Dalgıç, O; Demir, M; Doğduş, M; Erdoğan, A; Ergin, I; Genç, Ö; Güler, A; Güvendi Şengör, B; İbişoğlu, E; İlkay Yüce, E; Kaplan, M; Karabulut, D; Karabulut, U; Keskin Meriç, B; Kıvrak, T; Kocabaş, U; Murat, B; Murat, S; Naki Tekin, DD; Özçalık, E; Özdemir, I; Özgeyik, M; Özyurtlu, F; Şahin, Ş; Şen, T; Tüner, H; Urgun, ÖD; Uzman, O; Yavuz, V | 1 |
Kwon, HM; Lee, YS; Moon, HS; Nam, KW; Won, SH | 1 |
Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E | 1 |
Brinkmann, M; Diener, HC; Eschenfelder, CC; Gröschel, K; Grosse, GM; Hüsing, A; Kuklik, N; Michalski, D; Nabavi, D; Poli, S; Royl, G; Sparenberg, P; Stang, A; Weimar, C; Weissenborn, K | 1 |
Alt, E; Bessette, LG; Kim, DH; Mahesri, M; Najafzadeh, M; Schneeweiss, S; Shin, H; Wang, SV | 1 |
An, J; Cheetham, TC; Lang, DT; Lee, MS; Luong, T; Reynolds, K | 1 |
Chan, YH; Fong, KY; Lip, GYH; Tan, VH; Yeo, C | 1 |
Huang, KC; Lee, JK; Lin, DS; Lin, TT; Lo, HY | 1 |
Chu, YB; Dong, SJ; Gupta, P; Li, YH; Wu, B; Zhai, SD; Zhang, YJ | 1 |
Ghanima, W; Halvorsen, S; Jonasson, C; Rutherford, OW; Söderdahl, F | 2 |
Huang, Y; Liang, H; Rong, G; Wang, H; Wang, L | 1 |
Prabha, N; Singh, A; Yadav, H | 1 |
Belhassen, M; Cotté, FE; Dalon, F; Danchin, N; Falissard, B; Gollety, S; Hanon, O; Jacoud, F; Lefevre, C; Mahé, I; Nolin, M; Steg, PG; Van Ganse, E | 1 |
Huang, M; Liu, X; Ma, J; Ye, C; Zeng, C; Zeng, J | 1 |
Frol, S; Hudnik, LK; Oblak, JP; Šabovič, M; Sernec, LP | 1 |
Goya, M; Hirao, K; Kawabata, M; Maeda, S; Sasano, T; Takahashi, Y; Yagishita, A | 1 |
Bang, OY; Choi, HY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, JM; Lee, MY; On, YK; Park, YJ; Suh, HS; Won, MM | 1 |
Egred, M; Farag, M; Gorog, DA; Gue, YX; Spinthakis, N | 1 |
Chutinet, A; Diener, HC; Easton, JD; Granger, CB; Kleine, E; Marquardt, L; Meyerhoff, J; Sacco, RL; Zini, A | 1 |
Di Fusco, M; Friend, K; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Thomas, L; Yuce, H | 1 |
Böhm, M; Brueckmann, M; Connolly, S; Eikelboom, JW; Ewen, S; Ezekowitz, M; Millenaar, D; Schumacher, H; Slawik, J; Ukena, C; Wallentin, L; Yusuf, S | 1 |
Barnes, GD; Cuker, A; Dawwas, GK; Dietrich, E; Leonard, CE; Lewis, JD | 1 |
Alatawi, Y; Alghamdi, BS; Alshehri, FS; Balabagno, AO; Chen, Y; Durmanova, V; Evangelista, LS; Hromadka, T; Javor, J; Ji, Q; Jiao, J; Kralova, M; Kurdi, M; Labban, S; Li, X; Li, Y; Lv, Q; Minarik, G; Ocenasova, A; Pagsibigan, JS; Parnicka, Z; Reznakova, V; Shawkatova, I; Shen, ZJ; Tian, X; Tu, S; Tuazon, JA; Vaseckova, B; Wang, XY; Wang, Z; Xue, Y; Zeng, LX; Zhang, S; Zhang, ZH; Zuo, C | 1 |
Chaudhry, UA; Ezekowitz, MD; George, WT; Gracely, EJ; Harper, G; Harper, GR; Wolfe, CM | 1 |
Al-Khalili, F; Ehrenstein, V; Ghanima, W; Gislason, G; Halvorsen, S; Hohnloser, SH; Jenkins, A; Johnsen, SP; Linder, M; Madsen, M; Sulo, G; Tell, GS | 1 |
Chan, KA; Chen, HM; Lai, CL; Liao, MT; Lin, TT | 1 |
Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE | 1 |
Amin, A; Baser, O; Dina, O; Keshishian, A; Le, H; Liu, X; Mardekian, J; Rosenblatt, L; Trocio, J; Vo, L; Zhang, Q | 1 |
Cao, Q; Jacobs, MS; Jansman, FGA; Postma, MJ; Tieleman, RG; van Hulst, M; van Leent, MWJ | 1 |
Hernandez, I; Saba, S; Zhang, Y | 1 |
Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M | 1 |
Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ | 1 |
Cao, F; Henk, HJ; Mardekian, J; Odell, K; Patel, C; Price, K; Sands, GH; Singh, P; Singhal, S; Tan, W; Trocio, J; Tuell, K; Vo, L | 1 |
Jesus, PAP; Monteiro, JMC; Oliveira Filho, J; San-Martin, DL; Silva, BCG | 1 |
Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S | 1 |
Kyle, A; McBain, L | 1 |
Aguinaco, MR; Bustins, A; Campoy, D; Canals, T; Cerdá, M; Constans, M; Ene, G; Gabilondo, M; Jiménez, C; Johansson, E; Las Heras, G; López, M; Marzo, C; Mateo, J; Moya, Á; Oliver, A; Olivera, P; Perea, G; Plensa, E; Pons, V; Reverter, JC; Sánchez, E; Santamaría, A; Santos, N; Sorigue, M; Tàssies, D; Varela, A; Vicente, L | 1 |
Baser, O; Di Fusco, M; Friend, K; Gupta, K; Hamilton, M; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Steffel, J | 1 |
Andersson, NW; Lund, M; Melbye, M; Pasternak, B; Svanström, H | 1 |
Chang, Y; Crowther, M; Holbrook, A; Larsen, TB; Levine, MAH; Li, G; Lip, GYH; Mbuagbaw, L; Sun, X; Tang, J; Thabane, L; Witt, DM | 1 |
Aljohani, MM; Alsager, OA; Chinnappan, R; Cialla-May, D; Eissa, S; Popp, J; Weber, K; Zourob, M | 1 |
Abouelfath, A; Bénichou, J; Blin, P; Cottin, Y; Droz, C; Dureau-Pournin, C; Lassalle, R; Mismetti, P; Moore, N | 1 |
Chu, HM; Fang, RY; Fu, GH; Gao, F; Liu, J; Yu, YB | 1 |
Eto, A; Hiraoka, F; Nii, K; Tsutsumi, M | 1 |
Hirakawa, T; Ishida, K; Koretsune, Y; Kuroki, D; Ono, Y; Sumida, T; Urushihara, H; Yamashita, T; Yasaka, M | 1 |
Joung, B; Kim, JY; Kim, TH; Kim, YH; Lee, MH; Pak, HN; Park, J; Shim, J; Uhm, JS; Yu, HT | 1 |
Rubboli, A | 1 |
Atarashi, H; Fukaya, T; Inoue, H; Koretsune, Y; Okumura, K; Taniguchi, A; Uchiyama, S; Yamashita, T; Yasaka, M | 1 |
Aonuma, K; Goya, M; Harada, T; Hirao, K; Kihara, Y; Nakahara, S; Nakano, Y; Nogami, A; Nuruki, N; Origasa, H; Otani, R; Sekiguchi, Y; Yoshida, K; Yoshida, Y | 1 |
Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, A; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H | 1 |
Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L | 1 |
Hinotsu, S; Kano, MR; Kitamura, Y; Koyama, T; Miller, MW; Ogawa, A; Ohshima, A; Sendo, T; Tanaka, HY; Zamami, Y | 1 |
Dalmau, FG | 1 |
Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N | 1 |
Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD | 1 |
Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP | 1 |
Ahmad, Y; Lip, GY | 2 |
Verheugt, FW | 1 |
Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J | 1 |
Baglin, T | 1 |
Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S | 1 |
Adam, G; Akbal, E; Asik, M; Bilen, Oİ; Binnetoglu, E; Gunes, F; Sen, H; Temiz, A; Ukinc, K | 1 |
Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
Chang, CH; Chen, JH; Lin, LJ; Yang, YH | 1 |
Cordova, EG; del Aguila, D; Salazar, CA | 1 |
Hürlimann, D; Noll, G; Noll, S | 1 |
Expósito, V; Fernández-Fresnedo, G; Seras, M | 1 |
Banfi, R; Fallani, F; Palazzi, N; Pugi, A | 1 |
Gonschior, AK; Heinrich-Nols, J; Kansal, AR; Noack, H; Sorensen, SV; Sunderland, T; Zheng, Y | 1 |
Beyer-Westendorf, J; Daschkow, K; Ebertz, F; Endig, H; Förster, K; Gelbricht, V; Köhler, C; Michalski, F; Pannach, S; Sahin, K; Tittl, L; Weiss, N; Werth, S | 1 |
Eikelboom, JW; Weitz, JI | 1 |
Hsieh, CY; Hsu, JC; Lu, CY; Yang, YH | 1 |
Ageno, W; Riva, N | 1 |
Marietta, M | 1 |
Connolly, SJ; Ezekowitz, MD; Fukaya, T; Hori, M; Kleine, E; Reilly, PA | 1 |
Fujikawa, T; Imagawa, A; Ueta, E | 1 |
Demir, S; Kendirli, MT; Ozdag, MF; Togrol, RE | 1 |
Athanasakis, K; Bilitou, A; Karampli, E; Kyriopoulos, J; Tsounis, D | 1 |
Bartels, DB; Bykov, K; Huybrechts, K; Schneeweiss, S; Seeger, JD; Zint, K | 1 |
Shaw, P; Wood, M | 1 |
Eikelboom, J; Weitz, JI | 1 |
Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
Dagres, N; Hindricks, G; Jokic, V; Lane, DA; Larsen, TB; Lip, GY; Potpara, TS | 1 |
Acin, F; Bleda, S; Cañibano, C; De Haro, J; Varela, C | 1 |
Fonarow, GC; Gersh, BJ; Kim, S; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Thomas, L | 1 |
Aoyagi, H; Asano, M; Hirao, K; Kawaguchi, N; Kurabayashi, M; Nakamura, T; Okishige, K; Sasano, T; Shimura, T; Suzuki, H; Yamashita, M; Yamauchi, Y | 1 |
Kjældgaard, JN; Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F | 1 |
Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B | 1 |
Aisenberg, J; Brueckmann, M; Chatterjee, P; Connolly, S; Desai, J; Ezekowitz, M; Flack, KF; Ilgenfritz, J; Kolb, JM; Reilly, P; Wallentin, LC; Yusuf, S | 1 |
Bhatt, DL; Vaduganathan, M | 1 |
Alings, M; Connolly, SJ; Darius, H; Diaz, R; Diener, HC; Eikelboom, J; Ezekowitz, MD; Joyner, CD; Lewis, BS; Oldgren, J; Parekh, A; Pogue, J; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Xavier, D; Yusuf, S; Zhu, J | 1 |
Vojácek, J | 1 |
Ibrahim, S; Jespersen, J; Poller, L | 1 |
Connolly, SJ; Ezekowitz, MD; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
Thompson, CA | 1 |
Neilson, RF | 1 |
Aikens, TH; Chernick, MR; Connolly, SJ; Ezekowitz, MD; Lip, GY; Parekh, A; Pogue, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
Garnock-Jones, KP | 1 |
Eikelboom, JW; Haroun, MJ; Paikin, JS | 1 |
Beasley, BN; Temple, R; Unger, EF | 1 |
Belavic, JM | 1 |
Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C | 1 |
Bartholomew, JR; Wartak, SA | 1 |
Yates, SW | 1 |
Kamal, AK; Khan, M; Raza, E | 1 |
Brueckmann, M; Connolly, S; Ezekowitz, M; Flaker, G; Hohnloser, SH; Noack, H; Reilly, P; Wallentin, L; Yusuf, S | 1 |
Cowie, MR; Gani, R; Kansal, AR; Pan, F; Plumb, JM; Robinson, P; Sorensen, SV | 1 |
Wise, J | 1 |
Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C | 1 |
Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
McKeage, K | 1 |
Ansell, J; Mantha, S | 1 |
Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
Fareed, J; Kalodiki, E; Lewis, B | 1 |
Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C | 1 |
Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV | 1 |
Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC | 1 |
Barrios, V; Escobar, C | 1 |
Sinnaeve, PR; Van de Werf, F | 1 |
Brueckmann, M; Connolly, SJ; Dans, AL; Eikelboom, JW; Ezekowitz, M; Nakamya, J; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
Annemans, L; Thijs, V; Wouters, H | 1 |
Sarah, S | 1 |
33 review(s) available for dabigatran and Embolus
Article | Year |
---|---|
Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2023 |
Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke | 2023 |
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Cost of Illness; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Safety; Stroke; Thiazoles; Warfarin | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Diseases; Heart Ventricles; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombosis; Warfarin | 2021 |
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2017 |
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide.
Topics: Androgen Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Benzamides; Dabigatran; Drug Interactions; Embolism; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2019 |
Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Warfarin | 2018 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2019 |
[The new oral anticoagulants in special populations].
Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis | 2012 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolism; Humans; Quality-Adjusted Life Years; Stroke; Technology Assessment, Biomedical | 2013 |
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Topics: Amidines; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Drug Administration Schedule; Embolism; Female; Humans; Male; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Stroke; Vitamin K; Warfarin | 2014 |
[Oral anticoagulation in chronic kidney disease with atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke | 2015 |
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Renal Insufficiency, Chronic; Stroke; Warfarin | 2016 |
Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Humans; Ischemia; Leg; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Stroke; Warfarin | 2012 |
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Humans; Pyrazoles; Pyridones; Risk Factors; Stroke; Warfarin | 2011 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Economics, Pharmaceutical; Embolism; Humans; Pyridines; Quality-Adjusted Life Years; Stroke; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Evidence-Based Medicine; Hemorrhage; Humans; Risk Factors; Stroke | 2012 |
The pharmacology and therapeutic use of dabigatran etexilate.
Topics: Antithrombins; Benzimidazoles; Dabigatran; Drug Interactions; Drug Monitoring; Embolism; Humans; Prodrugs; Pyridines; Stroke | 2013 |
16 trial(s) available for dabigatran and Embolus
Article | Year |
---|---|
Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Stroke; Treatment Outcome; United States; Warfarin | 2023 |
The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2020 |
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Dabigatran; Double-Blind Method; Embolic Stroke; Embolism; Female; Foramen Ovale, Patent; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Young Adult | 2021 |
When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Incidence; Intraoperative Care; Male; Middle Aged; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Whole Blood Coagulation Time | 2019 |
Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Perioperative Period; Prospective Studies; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Stroke; Treatment Outcome | 2013 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes Mellitus; Embolism; Female; Hemorrhage; Humans; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Stroke | 2014 |
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Glomerular Filtration Rate; Humans; Internationality; Kidney; Male; Middle Aged; Models, Biological; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2014 |
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score.
Topics: Aged; Asian People; Creatinine; Dabigatran; Embolism; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Stroke; Warfarin | 2015 |
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor VIIa; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Prognosis; Risk Factors; Stroke; Warfarin | 2016 |
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chemoprevention; Dabigatran; Embolism; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Male; Prevalence; Prospective Studies; Stroke; Warfarin | 2017 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution; Dabigatran; Double-Blind Method; Dyspepsia; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Liver; Male; Middle Aged; Myocardial Infarction; Prodrugs; Proportional Hazards Models; Pyridines; Stroke; Warfarin | 2009 |
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyridines; Risk Factors; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2010 |
Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Follow-Up Studies; Humans; Prospective Studies; Pyridines; Risk Factors; Stroke; Vitamin K; Warfarin | 2011 |
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.
Topics: Aged, 80 and over; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolism; Female; Follow-Up Studies; Humans; Male; Models, Economic; Pyridines; Stroke; United Kingdom | 2012 |
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
87 other study(ies) available for dabigatran and Embolus
Article | Year |
---|---|
Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Cause of Death; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Sex Factors; Stroke; Thromboembolism; Turkey | 2021 |
Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Embolism; Hemorrhage; Humans; Risk Factors; Stroke; Warfarin | 2022 |
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Japan; Stroke | 2022 |
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cohort Studies; Dabigatran; Embolism; Humans; Ischemic Stroke; Renal Insufficiency, Chronic; Rivaroxaban; United States | 2022 |
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Multimorbidity; Pyridones; Risk Assessment; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Liver Diseases; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke; Vitamin K; Young Adult | 2023 |
Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thromboembolism; Vitamin K; Warfarin | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Flecainide; Hemorrhage; Hospitalization; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; Sotalol; Stroke; United States | 2023 |
Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Prospective Studies; Stroke; Vitamins | 2023 |
Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Embolism; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2023 |
Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
Topics: Aged; Anticoagulants; Atrial Fibrillation; China; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Treatment Outcome | 2020 |
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Norway; Patient Safety; Pyrazoles; Pyridones; Registries; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2020 |
Persistence, effectiveness and safety of dabigatran in "real-world" Chinese patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Brain Ischemia; China; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Stroke; Time Factors; Treatment Outcome | 2020 |
A Rare Case Report of Dabigatran Induced Oral Ulcers.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Embolism; Female; Humans; Oral Ulcer | 2020 |
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Rivaroxaban; Stroke; Warfarin | 2020 |
Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Secondary Prevention; Stroke | 2020 |
A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Loss, Surgical; Carotid Artery Diseases; Cerebral Infarction; Dabigatran; Digestive System Surgical Procedures; Elective Surgical Procedures; Embolism; Endoscopy; Factor Xa Inhibitors; Female; Humans; Male; Myocardial Infarction; Orthopedic Procedures; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thromboembolism; Urologic Surgical Procedures; Vascular Surgical Procedures | 2020 |
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Coronary Artery Disease; Dabigatran; Embolism; Female; Health Care Costs; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Peripheral Arterial Disease; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2021 |
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Coronary Disease; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Medication Adherence; Middle Aged; Polypharmacy; Proportional Hazards Models; Stroke; Warfarin | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Comparative Effectiveness Research; Dabigatran; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Ischemic Stroke; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Treatment Outcome; Warfarin | 2021 |
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Angiotensin II; Animals; Antithrombins; Atrial Fibrillation; Body Mass Index; Catheter Ablation; Cohort Studies; Dabigatran; Dogs; Embolism; Factor Xa Inhibitors; Female; Genotype; Hemorrhage; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Middle Aged; Norepinephrine; Obesity; Polymorphism, Single Nucleotide; Retrospective Studies; Rivaroxaban; Stroke; Sympathectomy | 2017 |
Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation.
Topics: Age Factors; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Transfusion; Cause of Death; Comparative Effectiveness Research; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Logistic Models; Male; Mortality; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke | 2017 |
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiology; Dabigatran; Embolism; Female; Hemorrhage; Hospital Charges; Humans; Male; Middle Aged; Netherlands; Propensity Score; Retrospective Studies; Sex Factors; Stroke | 2017 |
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pennsylvania; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hospitalization; Humans; Inpatients; Male; Middle Aged; Outpatients; Patient Discharge; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
Anticoagulation in patients with cardiac manifestations of Chagas disease and cardioembolic ischemic stroke.
Topics: Aged; Anticoagulants; Brain Ischemia; Chagas Cardiomyopathy; Dabigatran; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Retrospective Studies; Stroke; Warfarin | 2018 |
Renal function monitoring in patients prescribed dabigatran in the Compass Health Primary Health Organisation: a quality improvement audit.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Kidney Function Tests; Male; Medical Audit; Middle Aged; Quality Improvement; Stroke; Young Adult | 2018 |
Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants.
Topics: Administration, Oral; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Peripheral Arterial Disease; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2018 |
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome | 2018 |
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate.
Topics: Anticoagulants; Aptamers, Nucleotide; Atrial Fibrillation; Dabigatran; Embolism; Gene Library; Hemorrhage; Humans; Ligands; SELEX Aptamer Technique; Sensitivity and Specificity; Stroke | 2018 |
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Stroke; Treatment Outcome; Vitamin K | 2019 |
[A Case of Successful Drug Management with Dabigatran and Idarucizumab to Address Embolic and Hemorrhagic Complications for Asymptomatic and Traumatic Subdural Hematoma with Non-valvular Atrial Fibrillation].
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Embolism; Female; Hematoma, Subdural; Humans | 2018 |
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Embolism; Female; Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Japan; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2019 |
Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles | 2019 |
Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Monitoring; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Stroke; Thromboembolism; Time Factors; Treatment Outcome | 2019 |
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Prescriptions; Embolism; Female; Hemorrhage; Humans; Incidence; Japan; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Stroke; Warfarin; Young Adult | 2019 |
Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Embolism; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Premedication; Retrospective Studies; Risk Assessment; Stroke; Tennessee; Treatment Outcome; Warfarin | 2013 |
New oral anticoagulants in atrial fibrillation forever?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Stroke | 2013 |
Gastrointestinal bleeding associated with dabigatran in a patient with panhypopituitarism.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Embolism; Female; Gastrointestinal Hemorrhage; Humans; Hypopituitarism; Treatment Outcome | 2014 |
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Markov Chains; Pyridines; Stroke; Taiwan; Warfarin | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Hemorrhage; Hospitals, General; Humans; Italy; Male; Middle Aged; Retrospective Studies | 2014 |
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Models, Theoretical; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2014 |
Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Embolism; Female; Germany; Hemorrhage; Humans; Intention to Treat Analysis; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Registries; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2015 |
'Realworld' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Ischemic Attack, Transient; Male; Stroke | 2015 |
Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Decision Support Techniques; Embolism; Evidence-Based Medicine; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2015 |
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Europe; Female; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
A case of a slightly symptomatic exfoliative oesophagitis.
Topics: Aged; Antithrombins; Coronary Vessels; Dabigatran; Drug Therapy, Combination; Embolism; Esophagitis; Esophagus; Humans; Lansoprazole; Male; Proton Pump Inhibitors | 2015 |
What Do Anticoagulants Say about Microemboli?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Rivaroxaban; Severity of Illness Index; Treatment Outcome; Ultrasonography, Doppler, Transcranial; Warfarin | 2015 |
Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Greece; Health Care Costs; Humans; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2015 |
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Evaluation; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Insurance Coverage; Male; Middle Aged; Myocardial Infarction; Polypharmacy; Propensity Score; Retrospective Studies; Stroke; Thrombophilia; Treatment Outcome; Warfarin; Young Adult | 2015 |
Pradaxa-induced esophageal ulcer.
Topics: Aged; Anticoagulants; Dabigatran; Embolism; Endoscopy, Gastrointestinal; Esophageal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Stomach; Ulcer; Warfarin | 2015 |
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; DNA-Binding Proteins; Drosophila Proteins; Embolism; Female; Hemorrhage; Humans; Male; Medicaid; Middle Aged; Mortality; Registries; Rivaroxaban; Stroke; Transcription Factors; Treatment Outcome; United States; Warfarin | 2016 |
Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain; Brain Ischemia; Cryosurgery; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin | 2017 |
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Drug Administration Schedule; Embolism; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Gastrointestinal Hemorrhage; Humans; Neoplasms; Stroke; Warfarin | 2017 |
[The results of the RE-lY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Humans; Pyridines; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Hemorrhage; Humans; Incidence; International Normalized Ratio; Pyridines; Stroke; Warfarin | 2009 |
Newly identified events in the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Pyridines | 2010 |
First oral thrombin inhibitor enters market: drug does not require clinicians to monitor INR.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Monitoring; Embolism; Humans; International Normalized Ratio; Pyridines; Stroke; Thrombin | 2010 |
Warfarin: is the end nigh? Please?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Warfarin | 2010 |
Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Interactions; Economics, Pharmaceutical; Embolism; Humans; Prodrugs; Pyridines; Randomized Controlled Trials as Topic; Stroke | 2011 |
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Embolism; Hemorrhage; Humans; Stroke; Therapeutic Equivalency; United States; United States Food and Drug Administration; Warfarin | 2011 |
Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Approval; Embolism; Humans; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
Dabigatran: will it change clinical practice?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Stroke; United States; Warfarin | 2011 |
What are the emerging therapeutic alternatives to warfarin in stroke patients? How would the results of RE-LY benefit Pakistanis?
Topics: Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Embolism; Evidence-Based Medicine; Humans; International Normalized Ratio; Pakistan; Pyridines; Stroke; Treatment Outcome; Warfarin | 2011 |
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Electrocardiography; Embolism; Female; Follow-Up Studies; Heart Rate; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Tachycardia, Paroxysmal; Time Factors; Treatment Outcome; Warfarin | 2012 |
NICE backs new oral anticoagulant for stroke prevention.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Approval; Drug Monitoring; Embolism; Humans; Prodrugs; Pyridines; Stroke | 2012 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Embolectomy; Embolism; Enoxaparin; Fatal Outcome; Femoral Artery; Humans; International Normalized Ratio; Male; Phenprocoumon; Vertebrobasilar Insufficiency | 2012 |
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Guideline Adherence; Hemorrhage; Humans; Patient Selection; Practice Guidelines as Topic; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
New oral anticoagulant in atrial fibrillation: are they comparable?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Spain; Stroke; Vitamin K; Warfarin | 2012 |
Do ingredients make the difference?: finding the best cocktail of an anticoagulant with antiplatelets.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Female; Humans; Male; Platelet Aggregation Inhibitors; Pyridines; Stroke; Warfarin | 2013 |
Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
Topics: Adult; Aged; Atrial Fibrillation; Belgium; Benzimidazoles; Confidence Intervals; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Middle Aged; Pyridines; Quality-Adjusted Life Years; Stroke | 2013 |